Vimarsana
Biggest News Aggregation in the World

Page 7 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

AstraZeneca: Truqap Plus Faslodex Approved In US For HR+ Breast Cancer - Vimarsana News

AstraZeneca: Truqap Plus Faslodex Approved In US For HR+ Breast Cancer

British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that the U.S. Food and Drug Administration or FDA has approved its Truqap (capivasertib) in combination with Faslodex (fulvestrant) to treat patients with advanced hormone receptor or HR-positive breast cancer.

AstraZeneca's Truqap approved in the US for HR-positive breast cancer - Vimarsana News

AstraZeneca's Truqap approved in the US for HR-positive breast cancer

AstraZeneca's Truqap approved in the US for HR-positive breast cancer

AstraZeneca gets US approval for breast cancer treatment - Vimarsana News

AstraZeneca gets US approval for breast cancer treatment

AstraZeneca’s ‘Truqap’, or capivasertib, in combination with ‘Faslodex’, or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

AstraZeneca : Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer -November 14, 2023 at 02:06 am EST - Vimarsana News

AstraZeneca : Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer -November 14, 2023 at 02:06 am EST

Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient cohort which showed a 22% reduction in the risk of death versus chemotherapy alone ...

Durvalumab Plus Chemo Wins Approval in China For Advanced/Metastatic Biliary Tract Cancer - Vimarsana News

Durvalumab Plus Chemo Wins Approval in China For Advanced/Metastatic Biliary Tract Cancer

China’s National Medical Products Administration has approved durvalumab plus gemcitabine and cisplatin for frontline use in adult patients with locally advanced or metastatic biliary tract cancer.